Amplification of MYCN strongly predicts a poorer prognosis for both tumor progression and overall survival [6,7,8], and, consequently, the protein product N-Myc is a prime target for new drugs for NB treatment [9,10,11]. Here, MYCN is linked to neuroblastoma.